• 1
    Romisch J (2002) Factor VII activating protease (FSAP): a novel protease in hemostasis. Biol Chem 383, 11191124.
  • 2
    Kanse SM, Parahuleva M, Muhl L, Kemkes-Matthes B, Sedding D & Preissner KT (2008) Factor VII-activating protease (FSAP): vascular functions and role in atherosclerosis. Thromb Haemost 99, 286289.
  • 3
    Choi-Miura NH, Tobe T, Sumiya J, Nakano Y, Sano Y, Mazda T & Tomita M (1996) Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator. J Biochem 119, 11571165.
  • 4
    Etscheid M, Hunfeld A, Konig H, Seitz R & Dodt J (2000) Activation of proPHBSP, the zymogen of a plasma hyaluronan binding serine protease, by an intermolecular autocatalytic mechanism. Biol Chem 381, 12231231.
  • 5
    Kannemeier C, Feussner A, Stohr HA, Weisse J, Preissner KT & Romisch J (2001) Factor VII and single-chain plasminogen activator-activating protease: activation and autoactivation of the proenzyme. Eur J Biochem 268, 37893796.
  • 6
    Altincicek B, Shibamiya A, Trusheim H, Tzima E, Niepmann M, Linder D, Preissner KT & Kanse SM (2006) A positively charged cluster in the epidermal growth factor-like domain of Factor VII-activating protease (FSAP) is essential for polyanion binding. Biochem J 394, 687692.
  • 7
    Nakazawa F, Kannemeier C, Shibamiya A, Song Y, Tzima E, Schubert U, Koyama T, Niepmann M, Trusheim H, Engelmann B et al. (2005) Extracellular RNA is a natural cofactor for the (auto-)activation of Factor VII-activating protease (FSAP). Biochem J 385, 831838.
  • 8
    Jiang D, Liang J & Noble PW (2007) Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 23, 435461.
  • 9
    Brown MR & Kornberg A (2004) Inorganic polyphosphate in the origin and survival of species. Proc Natl Acad Sci USA 101, 1608516087.
  • 10
    Ruiz FA, Lea CR, Oldfield E & Docampo R (2004) Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 279, 4425044257.
  • 11
    Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R & Morrissey JH (2006) Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 103, 903908.
  • 12
    Choi-Miura NH, Saito K, Takahashi K, Yoda M & Tomita M (2001) Regulation mechanism of the serine protease activity of plasma hyaluronan binding protein. Biol Pharm Bull 24, 221225.
  • 13
    Hunfeld A, Etscheid M, Konig H, Seitz R & Dodt J (1999) Detection of a novel plasma serine protease during purification of vitamin K-dependent coagulation factors. FEBS Lett 456, 290294.
  • 14
    Romisch J, Vermohlen S, Feussner A & Stohr H (1999) The FVII activating protease cleaves single-chain plasminogen activators. Haemostasis 29, 292299.
  • 15
    Wygrecka M, Morty RE, Markart P, Kanse SM, Andreasen PA, Wind T, Guenther A & Preissner KT (2007) Plasminogen activator inhibitor-1 is an inhibitor of factor VII-activating protease in patients with acute respiratory distress syndrome. J Biol Chem 282, 2167121682.
  • 16
    Muhl L, Nykjaer A, Wygrecka M, Monard D, Preissner KT & Kanse SM (2007) Inhibition of PDGF-BB by Factor VII-activating protease (FSAP) is neutralized by protease nexin-1, and the FSAP–inhibitor complexes are internalized via LRP. Biochem J 404, 191196.
  • 17
    Roemisch J, Feussner A, Nerlich C, Stoehr HA & Weimer T (2002) The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP). Blood Coagul Fibrinolysis 13, 433441.
  • 18
    Sedding D, Daniel JM, Muhl L, Hersemeyer K, Brunsch H, Kemkes-Matthes B, Braun-Dullaeus RC, Tillmanns H, Weimer T, Preissner KT et al. (2006) The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation. J Exp Med 203, 28012807.
  • 19
    Willeit J, Kiechl S, Weimer T, Mair A, Santer P, Wiedermann CJ & Roemisch J (2003) Marburg I polymorphism of factor VII-activating protease: a prominent risk predictor of carotid stenosis. Circulation 107, 667670.
  • 20
    Wasmuth HE, Tag CG, Van deLeurE, Hellerbrand C, Mueller T, Berg T, Puhl G, Neuhaus P, Samuel D, Trautwein C et al. (2008) The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. Hepatology 49, 775780.
  • 21
    Roderfeld M, Weiskirchen R, Atanasova S, Gressner AM, Preissner KT, Roeb E & Kanse SM (2008) Altered factor VII activating protease expression in murine hepatic fibrosis and its influence on hepatic stellate cells. Liver Int 29, 686691.
  • 22
    Edelberg JM, Reilly CF & Pizzo SV (1991) The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a). J Biol Chem 266, 74887493.
  • 23
    Kannemeier C, Al-Fakhri N, Preissner KT & Kanse SM (2004) Factor VII-activating protease (FSAP) inhibits growth factor-mediated cell proliferation and migration of vascular smooth muscle cells. FASEB J 18, 728730.
  • 24
    Shibamiya A, Muhl L, Tannert-Otto S, Preissner KT & Kanse SM (2007) Nucleic acids potentiate Factor VII-activating protease (FSAP)-mediated cleavage of platelet-derived growth factor-BB and inhibition of vascular smooth muscle cell proliferation. Biochem J 404, 4550.
  • 25
    Alter SC, Metcalfe DD, Bradford TR & Schwartz LB (1987) Regulation of human mast cell tryptase. Effects of enzyme concentration, ionic strength and the structure and negative charge density of polysaccharides. Biochem J 248, 821827.
  • 26
    Kovanen PT (2007) Mast cells: multipotent local effector cells in atherothrombosis. Immunol Rev 217, 105122.
  • 27
    Clark JE & Wood HG (1987) Preparation of standards and determination of sizes of long-chain polyphosphates by gel electrophoresis. Anal Biochem 161, 280290.
  • 28
    Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT & Pannekoek H (1990) Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 265, 1302913035.
  • 29
    Olson ST & Shore JD (1981) Binding of high affinity heparin to antithrombin III. Characterization of the protein fluorescence enhancement. J Biol Chem 256, 1106511072.
  • 30
    Rezaie AR (2006) Pentasaccharide enhances the inactivation of factor Xa by antithrombin by promoting the assembly of a Michaelis-type intermediate complex. Demonstration by rapid kinetic, surface plasmon resonance, and competitive binding studies. Biochemistry 45, 53245329.
  • 31
    Muhl L, Hersemeyer K, Preissner KT, Weimer T & Kanse SM (2009) Structure–function analysis of factor VII activating protease (FSAP): sequence determinants for heparin binding and cellular functions. FEBS Lett 583, 19941998.
  • 32
    Garg HG, Cindhuchao N, Quinn DA, Hales CA, Thanawiroon C, Capila I & Linhardt RJ (2002) Heparin oligosaccharide sequence and size essential for inhibition of pulmonary artery smooth muscle cell proliferation. Carbohydr Res 337, 23592364.
  • 33
    Galuska SP, Geyer R, Muhlenhoff M & Geyer H (2007) Characterization of oligo- and polysialic acids by MALDI-TOF-MS. Anal Chem 79, 71617169.
  • 34
    Hernandez-Ruiz L, Valverde F, Jimenez-Nunez MD, Ocana E, Saez-Benito A, Rodriguez-Martorell J, Bohorquez JC, Serrano A & Ruiz FA (2007) Organellar proteomics of human platelet dense granules reveals that 14-3-3ζ is a granule protein related to atherosclerosis. J Proteome Res 6, 44494457.
  • 35
    Lindstedt L, Lee M & Kovanen PT (2001) Chymase bound to heparin is resistant to its natural inhibitors and capable of proteolyzing high density lipoproteins in aortic intimal fluid. Atherosclerosis 155, 8797.
  • 36
    Lindstedt L, Lee M, Castro GR, Fruchart JC & Kovanen PT (1996) Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid. J Clin Invest 97, 21742182.
  • 37
    Gallagher JT & Walker A (1985) Molecular distinctions between heparan sulphate and heparin. Analysis of sulphation patterns indicates that heparan sulphate and heparin are separate families of N-sulphated polysaccharides. Biochem J 230, 665674.
  • 38
    Miller MJ, Costello CE, Malmstrom A & Zaia J (2006) A tandem mass spectrometric approach to determination of chondroitin/dermatan sulfate oligosaccharide glycoforms. Glycobiology 16, 502513.